CANCER IMMUNOTHERAPY: WILL IT WORK FOR...
2
CANCER IMMUNOTHERAPY: WILL IT WORK FOR MY PATIENT? Tumor Mutational Burden (TMB) is a validated, quantitative genomic biomarker associated with response to immunotherapy 1 WHICH PATIENTS ARE MOST LIKELY TO RESPOND TO IMMUNOTHERAPY? High Treatment Costs Potential Toxic Side Effects Immunotherapy response varies widely, making it difficult for physicians to know whether immunotherapy will be effective for a given patient. 2-5 Comprehensive genomic profiling using FoundationOne can help to predict immunotherapy response through the measurement of your patient’s Tumor Mutational Burden (TMB) Durable Response Manageable Side Effects PREDICT BETTER WITH INCREASED CONFIDENCE Increased TMB levels have shown to be a promising indicator for response to immunotherapy. 1-9 Percent Progression-free Using whole exome sequencing, higher TMB was correlated with prolonged progression-free survival 6 TMB was shown to be higher in patients who responded compared with non-responders 1 Patients with >100 mutations identified experienced improved survival 7 In NSCLC patients treated using anti-PD-1 therapy (TMB measured by whole exome sequencing) In metastatic urothelial carcinoma patients (TMB measured using FoundationOne) In melanoma patients treated using anti-PD-1/PD-L1 therapy (TMB measured by whole exome sequencing) Other patients do not respond well to cancer immunotherapy and can experience: In certain patients, cancer immunotherapy has been shown to be effective, with outcomes like: High neoantigen burden Low neoantigen burden P<0.001 SD/PD CR/PR ®
Transcript of CANCER IMMUNOTHERAPY: WILL IT WORK FOR...
CANCER IMMUNOTHERAPY:WILL IT WORK FOR MY PATIENT?
Tumor Mutational Burden (TMB) is a validated, quantitative genomicbiomarker associated with response to immunotherapy1
WHICH PATIENTS ARE MOST LIKELY TO RESPOND TO IMMUNOTHERAPY?
High Treatment Costs Potential Toxic Side Effects
Immunotherapy response varies widely, making it difficult for physicians to know
whether immunotherapy will be effective for a given patient.2-5
Comprehensive genomic profiling using FoundationOne can help to predict
immunotherapy response through the measurement of your patient’s
Tumor Mutational Burden (TMB)
Durable Response Manageable Side Effects
PREDICT BETTER WITHINCREASED CONFIDENCE
Increased TMB levels have shown to be a promising indicator for response to immunotherapy.1-9
Per
cen
t P
rogr
essi
on
-fre
e
Using whole exome sequencing, higher TMB was correlated with prolonged
progression-free survival6
TMB was shown to be higher in patients who responded compared
with non-responders1
Patients with >100 mutations identified experienced
improved survival7
In NSCLC patients treated using anti-PD-1 therapy(TMB measured by whole exome sequencing)
In metastatic urothelial carcinoma patients(TMB measured using FoundationOne)
In melanoma patients treated using anti-PD-1/PD-L1 therapy (TMB measured by whole exome sequencing)
Other patients do not respond well to
cancer immunotherapy and can experience:
In certain patients, cancer immunotherapy
has been shown to be effective, with outcomes like:
High neoantigen burdenLow neoantigen burden
P<0.001
SD/PD CR/PR
®
IMMUNE CHECKPOINTRESPONSE PREDICTION
SAME FOUNDATIONONE PIPELINE1 2 3
Speak to your representative or visit
FoundationOne.com
FOUNDATIONONE:A RELIABLE AND ACCURATE MEASUREMENT FOR TMB
TURN YOUR PATIENT’S TMB INTO A TREATMENT PLAN
50%
40%
30%
20%
10%
0%
Bas
al c
ell c
ance
r
*Mal
ign
ant
mel
ano
ma
Mer
kel c
ell c
arci
no
ma
Ped
iatr
ic b
rain
can
cers
Gas
tric
can
cers
Ute
rin
e, e
nd
om
etri
al
Sarc
om
ato
id c
arci
no
ma
of
the
lun
g
Soft
tis
sue
sarc
om
a
Carc
ino
ma
of
un
kno
wn
pri
mar
y
**B
lad
der
car
cin
om
a
Larg
e ce
ll lu
ng
can
cer
Cuta
neo
us
T-ce
ll ly
mp
ho
ma
Lym
ph
om
a
***N
on
-sm
all c
ell l
un
g ca
nce
r
Lun
g ca
rcin
osa
rco
ma
Leu
kem
ia
B-c
ell l
ym
ph
om
a
Par
ath
yro
id c
arci
no
ma
Lun
g sa
rco
ma
Ute
rin
e, o
ther
Per
cen
tage
of
Hig
h T
MB
Cas
es
FoundationOne Heme(mutations show promising Phase III clinical trial data)
*anti-PD-1 therapy **anti-PD-L1 therapy***anti-PD-1 and anti-PD-L1 therapies
FoundationOne
To help identify targeted therapies.
To help predict a greater likelihood of benefit from immunotherapy.
To help identify clinical trials.
For your cancer patients, you only have so much tissue to get it right.
So use the best method up front.
TUMOR TYPES WITH HIGH TMB ACROSS FOUNDATION MEDICINE DATABASE
High TMB = ≥20 mutations per megabase (Mb)
TMB using FoundationOne is a quantitative approach to predicting response to immunotherapies.
Patient Rank
HIGHTMB
INTERMEDIATETMB
LOWTMB
Mu
tati
on
s/M
b
SequencingLibrary
BiotinylatedDNA Baits
Genomic DNA
HybridizationCaptured
FFPE
OR
REFERENCES:1. Rosenberg JE, et al. . 2016;387(10031):1909-20. 2. Public Workshop—Complexities in personalized medicine: harmonizing companion diagnostics across a class of targeted
therapies, March 24, 2015. US Food and Drug Administration website. http://goo.gl/5bVk6y. Accessed August 4, 2015.3. Spigel DR, et al. . 2015;33 (suppl; abstr 8009).4. Paz-Ares LG, et al. . 2015;33 (suppl; abstr LBA109).5. Garon EB, et al. . 2015;372(21):2018-28.6. Rizvi NA, et al. . 2015;348(6230):124-8.7. Snyder A, et al. . 2014;371(23):2189-99.8. Campesato LF, et al. . 2015;6(33):34221-7.9. Le DT, et al. . 2015;372(26):2509-20.
©2016 Foundation Medicine, Inc. Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc. IO-S-001-20161104
Science
Lancet
J Clin OncolJ Clin Oncol
N Engl J Med
N Engl J MedOncotarget
GET STARTEDORDER TODAY
®
Disease Indication: Urothelial carcinoma Tumor Type: Urinary bladderMutations/Mb (rank): High TMB 30 mut/Mb (99%)Approved therapies: AtezolizumabReferences: Rosenberg JE, et al. , 2016
150 Second Street | Cambridge, MA 02141 | [email protected]
Lancet
ONE, EASY-TO-INTERPRET REPORT
FOR SOLID TUMORS
FOR HEMATOLOGICMALIGNANCIES
N Engl J Med
LIKELY POSSIBLE UNLIKELY
